Clinical Trial Detail

NCT ID NCT04223856
Title Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Enfortumab vedotin-ejfv + Pembrolizumab

Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.